SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Resectable NSCLCSeptember 25, 2026

Multi-omic profiling separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma

A multi-omic model separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma, in work published in the Journal of Thoracic Oncology on 1 September 2026. Across four independent validation cohorts it reached a median concordance index of 75.4%, and it stratified risk inside individual stages, including stage I disease.
Share

In brief

  • Integrated clinical, genomic and transcriptomic profiling was performed on 400 patients with resected stage IA to IIIA EGFR-mutant lung adenocarcinoma.
  • The multi-omic model reached a median concordance index of 75.4% across one internal and three external validation cohorts.
  • Transcriptomic features predicted recurrence risk more accurately than clinical or genomic variables used alone.
  • TP53 co-mutations, copy number alterations and APOBEC-associated mutational signatures increased with pathological stage. RBM10 co-mutations were enriched in tumours carrying L858R mutations and correlated with upregulation of WNT signalling and epithelial-mesenchymal transition.
  • The model separated recurrence risk within individual stages, including stage I. No hazard ratio, per-cohort index or follow-up duration is reported, and the authors state that prospective validation in larger cohorts will be required.

Study at a glance

  • Cohort: 400 patients with resected EGFR-mutant lung adenocarcinoma
  • Population: Pathological stage IA to IIIA
  • Profiling: Integrated clinical, genomic and transcriptomic data
  • Validation: One internal and three external cohorts
  • Performance: Median concordance index of 75.4%
  • Stated application: Identifying patients most likely to benefit from adjuvant EGFR TKI
  • Not reported: Per-cohort indices, hazard ratios, follow-up duration, recurrence numbers, prospective validation

A median concordance index of 75.4% across four validation cohorts

The model was built from clinical, genomic and transcriptomic data together and tested in one internal and three external cohorts, and the authors describe its performance as superior and reproducible. A concordance index measures how often two patients are ranked in the correct order for recurrence, so 75.4% describes discrimination and not an absolute risk for any patient. The abstract gives the median alone: no value for any single cohort, no confidence interval, and no figure for the stage-based approach the model is offered against.

TP53, copy number alterations and APOBEC signatures rose with stage, and RBM10 clustered with L858R

Genomic instability tracked with stage. TP53 co-mutations, copy number alterations and APOBEC-associated mutational signatures all increased with pathological stage, so they carry information that stage already carries. RBM10 co-mutations were enriched in tumours with L858R mutations and correlated with upregulation of WNT signalling and epithelial-mesenchymal transition, a correlation within this cohort with no recurrence figure attached to it. Transcriptomic features predicted recurrence more accurately than the clinical or genomic variables alone, although no figure is reported for those single-modality models.

Stratification inside stage I, against an adjuvant standard set by pathology alone

Adjuvant osimertinib is the standard of care for resected stage IB to IIIA EGFR-mutant disease following ADAURA, and adjuvant decisions are guided by pathological stage alone. The authors note that real-world data show up to 40% of patients remain disease-free at five years without it. The model stratified risk within individual stages, including stage I, and the authors state that it identified the patients most likely to benefit from adjuvant EGFR TKI. No trial is reported in which treatment was assigned on the basis of the model, so that benefit is a prediction about who is at risk rather than a measured effect of giving or withholding the drug.

“These findings define the molecular heterogeneity of early-stage EGFR-mutant LUAD and support multi-omic risk stratification to inform adjuvant EGFR TKI decisions beyond pathological stage.”Saw et al., Journal of Thoracic Oncology (2026)

The authors state that prospective validation in larger cohorts will be required to confirm the findings.

Sources

  1. Journal of Thoracic Oncology. Integrated multi-omic profiling enables recurrence risk stratification beyond pathological stage in resected EGFR-mutant lung adenocarcinoma (2026-09-01). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Stephanie Saw.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Resectable NSCLCImmunotherapies

Latest options in early-stage NSCLC: novel IO approaches for improved outcomes

S. Patel
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Prof. Martin Reck
Nov 04 2026
SPONSORED EXPERT TALK
Resectable NSCLCImmunotherapies

MDT-BRIDGE in Resectable and Borderline Resectable NSCLC

Prof. Martin Reck presents and discusses the phase 2 MDT-BRIDGE trial in resectable and borderline resectable non-small cell lung cancer in this on-demand expert talk.

M. Reck
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
Patient Cases
Oct 04 2024
ILCS 2024
Advanced NSCLCResectable NSCLC

Patient Cases & Open Questions

} 32 min

Nuria Maria Novoa
Oct 04 2024
ILCS 2024
Resectable NSCLC

Surgical Dilemmas: Defining Resectability for Optimal Patient Outcomes in the IO Era

} 27 min

N. Novoa
Biagio Ricciuti
Oct 04 2024
ILCS 2024
Targeted Therapies

Decoding Actionable Alterations: Insights from KRAS, HER2, and c-MET

} 25 min

B. Ricciuti
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Nikolaj Frost
Oct 31 2026
RESEARCH
Resectable NSCLCImmunotherapies

KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC

N. Frost
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2

T. CasconeP. Forde
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard
Oct 14 2026
RESEARCH
Resectable NSCLC

More lymph nodes examined at segmentectomy tracked with longer survival in early-stage NSCLC

J. Perentes
Oct 08 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung

R. StahelM. PérolA. AddeoS. Peters
Alfredo Addeo
Oct 05 2026
RESEARCH
Advanced NSCLCTargeted Therapies

A JCO review sets PACC mutations and exon 20 insertions apart from classical EGFR mutations in NSCLC

A. AddeoX. Le
Nikolaj Frost
Oct 04 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation

N. FrostM. ReckA. Cortellini
Oct 03 2026
RESEARCH
Advanced NSCLCResectable NSCLCTargeted Therapies

AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy

A. Calles